Nasdaq
$0.7492▼ 2.60%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $47.2MShares out 63.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 10.6After-hours26.10.07 08:52SCHEDULE 13GOwnership#●●●#●●●
Connect Biopharma Holdings Ltd
BML Investment Partners, L.P. has filed a Schedule 13G, disclosing its beneficial ownership in Connect Biopharma Holdings Ltd. This filing formalizes the entity's status as a major shareholder of the company.…more
$0.7492-2.60%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1After-hours26.10.02 06:184Ownership
Connect Biopharma Holdings Ltd
Insider Xanthopoulos Kleanthis Gabriel of Connect Biopharma Holdings Ltd reported a change in beneficial ownership of securities effective September 30, 2026. This filing provides the details of the insider's equity position change via Form 4.…more
$0.7492-2.60%vs prev closeView filingShare - 10.1After-hours26.10.02 06:174Ownership
Connect Biopharma Holdings Ltd
Insider Liu Jean I of Connect Biopharma Holdings Ltd reported a change in beneficial ownership of securities as of September 30, 2026. This filing serves as a standard Form 4 disclosure regarding insider holdings.…more
$0.7492-2.60%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.30Regular26.10.01 03:27#●●●#●●●#●●●
Connect Biopharma Reports Positive Phase 2 Results for COPD Therapy
Connect Biopharma announced that its COPD drug candidate, rademikibart, significantly reduced treatment failure rates in a Phase 2 clinical trial. While the positive efficacy data boosts development prospects, investors should monitor further clinical progress and regulatory milestones.…more
$0.7492-2.60%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.30Pre-market26.09.30 20:00
●●●●●●●● ●●●●● ●●●●●●
Connect Biopharma announced positive topline results from its Phase 2 study of rademikibart, which significantly reduced COPD exacerbations and treatment failure rates. The company plans to engage with the FDA to discuss a potential Phase 3 registrational program.…more
$0.7492-2.60%vs prev close - 9.15Regular26.09.16 00:46
●●●●●●●● ●●●●● ●●●●●●
Connect Biopharma hit a 52-week low after its rademikibart Phase 2 asthma trial failed to reach statistical significance for its primary endpoint. While the study met key secondary endpoints regarding lung function, the failure to hit the primary goal triggered a significant sell-off.…more
$0.7492-2.60%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report